Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL3483756 | 0.93 | DGKA (0.56) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL3310609 | 0.93 | DGKA (0.56) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL1614072 | 0.93 | DGKA (0.64) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL31373773 | 0.93 | DGKA (0.64) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL756143 | 0.93 | DGKA (0.64) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL1777438 | 0.93 | DGKA (0.64) | DGKAPRKCAPAMLMNAKDM4E | |
| Hexane SCHEMBL19611429 | 0.93 | DGKA (0.64) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL11889416 | 0.91 | DGKA (0.62) | DGKAPRKCAPAMLMNAKDM4E | |
| Heptane SCHEMBL916291 | 0.91 | DGKA (0.61) | DGKAPRKCAPAMLMNAKDM4E | |
| Ethyl Acetate SCHEMBL1238750 | 0.91 | ALDH1A1 (0.58) | DGKAPRKCALMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-7635684-B2 | treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-100413878-C | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2008-08-27 | — | — | CN | disclosed |
| CN-1744916-A | Preventive or remedy for diseases caused by hyperglycemia | KISSEI PHARMACEUTICAL (JP) | 2006-03-08 | — | — | CN | disclosed |
| US-20060035844-A1 | Preventive or remedy for diseases caused by hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| CN-1688597-A | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2005-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | UGGT1, GCKR, SLC5A1 | DGKA 2694/4885PRKCA 1913/4885PAM 2775/4885 |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | UGGT1, GCKR, SLC5A1 | DGKA 2694/4885PRKCA 1913/4885PAM 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.